As predictive biomarkers of response to immune checkpoint inhibitors (ICIs) remain a major
unmet clinical need in patients with urothelial carcinoma (UC), we sought to identify tissue …

Simple Summary The predominant histologic type of bladder cancer is urothelial carcinoma
(UC). Programmed cell death-ligand 1 (PD-L1) expression levels in UC tumors help …

Simple Summary Pembrolizumab, an immune checkpoint inhibitor, has shown therapeutic
benefit for advanced urothelial carcinoma (aUC) patients, but only a limited population …

Immune checkpoint inhibitors are associated with durable and well-tolerated responses in
metastatic urothelial carcinoma. Predicting which patients respond to therapy has been …

Background The identification of prognostic and/or predictive biomarkers for response to
immune checkpoint inhibitors (ICI) could help guide treatment decisions. Objective We …

Background The objective of this study was to determine the cutoff value of PD‐L1
expression that can predict response to immune checkpoint inhibitor (ICI) immunotherapy for …

Simple Summary Immune checkpoint inhibitors (ICIs) are standard treatment for
advanced/metastatic urothelial cancer (a/mUC) following progression on platinum agents …

Immune checkpoint inhibitor (ICI) is widely used and highly effective for some cancer
patients but may result in disease progression in others. Hyperprogressive disease in …

The mechanisms underlying the resistance to immune checkpoint inhibitors (ICIs) therapy in
metastatic urothelial carcinoma (mUC) patients are not clear. It is of great significance to …

Although advanced bladder cancer overall has a poor prognosis, a subset of patients
demonstrate durable response to immune checkpoint inhibitors. Evidence shows that the …